Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18056018 | 0.80 | HRH4 (0.53) | HRH4KCNN3PRKD3CLK2DYRK1A | |
| SCHEMBL19684529 | 0.80 | HRH4 (0.42) | HRH4KCNN3PRKD3CLK2DYRK1A | |
| SCHEMBL19033043 | 0.80 | HSD11B1 (0.36) | HRH4KCNN3PRKD3CLK2DYRK1A | |
| SCHEMBL25590761 | 0.80 | HRH4 (0.36) | HRH4KCNN3PRKD3CLK2DYRK1A | |
| SCHEMBL18711826 | 0.80 | HRH4 (0.36) | HRH4KCNN3PRKD3CLK2DYRK1A | |
| SCHEMBL19822712 | 0.78 | — | — | |
| SCHEMBL16478445 | 0.77 | HRH4 (0.34) | HRH4KCNN3NOTUM | |
| SCHEMBL19711586 | 0.75 | KMT2A (0.34) | HRH4 | |
| SCHEMBL784044 | 0.75 | GPR4 (0.30) | — | |
| SCHEMBL15187555 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9605018-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9156874-B2 | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-10-13 | — | — | US | disclosed |
| US-9095599-B2 | O-(substituted benzyl) phosphoramidate compounds and therapeutic use | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8980865-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130190320-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | GILEAD CALISTOGA LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | HRH4 2029/4885KCNN3 2354/4885PRKD3 477/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | HRH4 2029/4885KCNN3 2354/4885PRKD3 477/4885 |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | HRH4 426/4885KCNN3 3068/4885PRKD3 42/4885 |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | PYGL, PRKCZ, PHKG1 | HRH4 2432/4885KCNN3 1003/4885PRKD3 22/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | HRH4 4619/4885KCNN3 4544/4885PRKD3 1909/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | HRH4 3288/4885KCNN3 4585/4885PRKD3 1639/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | HRH4 3288/4885KCNN3 4585/4885PRKD3 1639/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | HRH4 2340/4885KCNN3 3450/4885PRKD3 1382/4885 |
| US-20150141363-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | HRH4 3288/4885KCNN3 4585/4885PRKD3 1639/4885 |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | HRH4 3369/4885KCNN3 4121/4885PRKD3 781/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | HRH4 3084/4885KCNN3 4418/4885PRKD3 1736/4885 |
| US-20130190320-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ERBB2, EGFR, ERBB3 | HRH4 1945/4885KCNN3 4614/4885PRKD3 482/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | HRH4 3369/4885KCNN3 4121/4885PRKD3 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.